Theranostic treatment for prostate cancer involves targeting prostate specific membrane antigen (PSMA) on prostate cancer cells – first with a radioactive molecule to reveal the cancer’s spread via a PET scan and then a similar radioactive molecule that kills cancer cells.
The ProsTIC program has three aims:
1. Accelerate clinical trial research: Expand the portfolio of clinical trials investigating the use of PSMA PET imaging and therapy targeting areas of high-impact need that are not currently being addressed.
2. Education and Leadership: Establish a global hub of excellence to educate doctors, scientists, patients and the community about the application and benefits of this new technology.
3. Discovery research: Further investigate next generation targets, develop biomarkers to predict and monitor response to PSMA therapy, optimise new combinations with PSMA therapy in pre-clinical models, explore the use of radio-guided surgery and artificial intelligence image interpretation.
Email: prostic@petermac.org
Company Details
- Founded
- -
- Address
- 305 Grattan Street, Melbourne,vic 3000,australia
- Industry
- Hospitals And Health Care
- NAICS
-
Health Care and Social AssistanceSocial Assistance
- Keywords
- Prostate Cancer, Theranostics, Prostate, Cancer, PSMA, Lutetium, Dosimetry, Prostatectomy, mCRPC, HRCaP, Clinical Trial, Lu-PSMA.
- HQ
- Melbourne, VIC
- Competitors
- Peter MacCallum Cancer Foundation Limited, Royal North Shore Hospital, Isotopia Molecular Imaging ltd, Prostate Cancer Foundation, EANM Artificial Intelligence Committee, ANZUP Cancer Trials Group Limited, GE HealthCare, Australian Cancer Research Foundation, Peter MacCallum Cancer Centre, Nuclear Medicine Residents Organization (NMRO) - ACNM.
Prostic Theranostics Questions
Prostic Theranostics's website is https://www.petermac.org/research/ProsTIC/about-prostic
Prostic Theranostics's LinkedIn profile is https://au.linkedin.com/company/prostic-theranostics
Prostic Theranostics's industry is
Hospitals and Health Care
Prostic Theranostics's top competitors are
Peter Maccallum Cancer Foundation Limited,
Royal North Shore Hospital,
Isotopia Molecular Imaging Ltd,
Prostate Cancer Foundation,
Eanm Artificial Intelligence Committee,
Anzup Cancer Trials Group Limited,
Ge Healthcare,
Australian Cancer Research Foundation,
Peter Maccallum Cancer Centre,
Nuclear Medicine Residents Organization (Nmro) - Acnm.
Prostic Theranostics's categories are Hospitals and Health Care
Prostic Theranostics's founding year is 2019
